Introduction
Rheumatoid arthritis (RA) is a destructive synovitis associated with rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA). The estimated heritability of RA is 68%.
1 RA is associated with HLA-DRB1 alleles encoding a 'shared epitope' (SE) amino-acid sequence in the third hypervariable region: 70 QKRAA 74 (HLA-DRB1*0401), 70 QRRAA 74 (HLA-DRB1*0101, *0404, *0405, *0408) and 70 RRRAA 74 (HLA-DRB1*1001). According to the HLA-DRB1 SE hypothesis, 2 structural differences among major histocompatibility complex class II molecules may influence their interaction with T-cell receptors, and thus influence RA pathogenesis. Presentation of citrullinated peptides appears to be affected by the HLA-DRB1 SE alleles. 3 HLA-DRB1 SE alleles are associated with both RF 4, 5 and ACPA. [6] [7] [8] Although RF and ACPA are strongly associated with each other, HLA-DRB1 SE has a much stronger association with ACPA than with RF. [9] [10] [11] [12] Most studies show no RA susceptibility effect of HLA-DRB1 SE independent of ACPA, 10, [13] [14] [15] but recently an effect on ACPA-negative RA has been described. 16, 17 Furthermore, there may be a hierarchy of risk among HLA-DRB1 SE alleles. Focusing on the 70-74 amino-acid sequence, QKRAA('S 2 ') alleles conferred greater RA susceptibility than the other HLA-DRB1 SE alleles ('S 3P ': QRRAA/RRRAA). 18, 19 Furthermore, dividing HLA-DRB1 QRRAA alleles into HLA-DRB1*04-QRRAA and HLA-DRB1*01-QRRAA subgroups, a per-allele hierarchy of risk was observed: *0401-QKRAA4*0404-QRRAA4 *0101-QRRAA4*1001-RRRAA. 20 Compound heterozygosity (*0401/*0404 heterozygosity) has been associated with a maximal genotypic risk for RA susceptibility and severity, [21] [22] [23] [24] [25] including vasculitis 26 and cardiovascular mortality. 27 It has also been proposed that certain HLA-DRB1 alleles protect against development of RA, compared with other HLA-DRB1 non-SE alleles. Proposed protective motifs include: the 70 DERAA 74 sequence, [28] [29] [30] [31] aspartic acid at position 70 (D  70 ) , 32, 33 , isoleucine at position 67 (I 67 ) 34 ) was 'neutral'. 35 The overlap between all these models makes comparison of the different models challenging, but, in a different cohort, we found that the D 70 model performed best. 20 In this study, we used HLA-DRB1 data from the UK Rheumatoid Arthritis Genetics Consortium 36 to validate the above-mentioned susceptibility and protective models for RA. Importantly, this cohort was large enough to stratify by both RF and ACPA.
Results
Characteristics of subjects 71.6% of RA cases were female, 72.3% were IgM RFpositive, 67.1% were ACPA-positive, 69.3% had erosions and 36.8% had nodules (Table 1) . Centre-specific data have been described previously. 12, 36 HLA-DRB1 shared epitope RA susceptibility alleles The frequency of HLA-DRB1 SE alleles and their association with RA have been reported previously.
12 S 2 and S 3P alleles were associated with susceptibility to RA, and to autoantibody-positive RA, compared with X (non-S) alleles (Table 2 ). There was a marginal effect of S 2 alleles, and no significant effect of S 3 alleles, on RF-negative and ACPA-negative ('double-autoantibody-negative') RA.
There was a possible protective effect of S 3D (odds ratio (OR) 0.80, 95% confidence intervals (CI) 0.67-0.96) that, following stratification by autoantibody status, only remained significant for RF-positive RA (Table 2) .
On a per-allele basis, each HLA-DRB1 SE allele group was associated both with RA and with all its autoantibody subgroups, except for double-autoantibodynegative RA (Table 2 , lower part).
Within the HLA-DRB1 SE alleles, there was a hierarchy of risk: *0401B*04044*0101B*1001, with a significant difference between *0404 and *0101 (P ¼ 0.0003), but not between *0404 and *0401 (P ¼ 0.20) or between *0101 and *1001 (P ¼ 0.93). For ACPA-positive RA, *0401 conferred significantly higher risk than *0404 (P ¼ 0.026). Stratifying by both RF and ACPA, most of the risk effect could be attributed to the ACPA-positive cases, but there remained a more modest association of *0401, *0404 and *0101 with ACPA-negative, RF-positive RA (Table 2) .
On a per-genotype basis (Table 3) , the same hierarchy of risk was observed, with the additional observation of a gene-dose effect. HLA-DRB1*0404/*0401 carried a greater risk of RA than *0404 homozygosity (P ¼ 0.033), but no greater risk than that conferred by *0401 homozygosity (P ¼ 0.70), with no suggestion of a departure from a log-additive risk model.
After adjusting for HLA-DRB1 SE status (Table 4) , a possible risk effect of HLA-DRB1*09 alleles was seen compared with other HLA-DRB1 non-SE alleles (OR 2.14 (1.40-3.27), P ¼ 0.00048).
Protective HLA-DRB1 alleles In this context, we define 'protection' as a negative effect on RA susceptibility compared with other non-HLA-DRB1 SE alleles. ORs were adjusted for the presence of an HLA-DRB1 SE allele by logistic regression (Table 4) . When the analysis was restricted to individuals with no copies of the HLA-DRB1 SE, very similar ORs were obtained (data not shown). The analysis was also repeated, omitting the imputed data from Oxford, and, apart from HLA-DRB1*03, the results were not substantively different (data not shown).
Initial analyses revealed no significant protective effect of DERAA, but significant protective effects of both D 70 (per-allele, HLA-DRB1 SE-adjusted OR 0.82 (95% CI 0.73-0.92), P ¼ 0.006) and I 67 (per-allele, HLA-DRB1 SE-adjusted OR 0.77 (95% CI 0.69-0.87), P ¼ 0.00001). Comparing the predictions of these last two models in more detail ( 37 the only difference between the predictions of Roudier's and the D 70 model is that the latter predicts a protective effect of HLA-DRB1*16, whereas according to Roudier it should be neutral. Comparing allele HLA-DRB1*16 to all others gave an OR ¼ 0.99 (95% CI 0.57-1.72, P ¼ 0.99), suggesting a neutral effect, but there were only 60 HLA-DRB1*16 alleles in the entire dataset, so the power to distinguish between these models is lacking.
Effects of combinations of susceptibility and protective HLA-DRB1 alleles Table 6 summarises the per-genotype effect of main susceptibility and protective allele groups described . Data are presented as odds ratios (95% confidence intervals). '-' signifies the numbers were too small to allow a meaningful analysis. . Data are presented as odds ratios (95% confidence intervals). A '-' signifies the numbers were too small to allow a meaningful analysis.
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Discussion
ACPA-positive and APCA-negative RA are clinically and genetically distinct subtypes of RA. 38 HLA-DRB1 SE alleles have been estimated to contribute 18% of the genetic variance of ACPA-positive RA, but 2.4% of the genetic variance of ACPA-negative RA. 1 We found that HLA-DRB1 SE alleles have a strong effect on the risk of ACPA-positive RA, a weaker effect on the risk of RF-positive, ACPA-negative RA, and no effect on RFnegative, ACPA-negative RA. This may explain variable reports of HLA-DRB1 SE susceptibility to ACPA-negative RA.
1,16,17 Furthermore, we report a protective effect of D 70 against RA, although, again, this is not seen in doubleautoantibody-negative patients. The simplest version of the 'shared epitope' model, treating all HLA-DRB1 SE alleles as equivalent in terms of RA susceptibility, has been an excellent working model thus far. Within the HLA-DRB1 SE alleles, we observed a hierarchy of risk: *0401B*04044*0101B *1001, supporting a division of the HLA-DRB1 SE into *04-SE ('high risk') and non-*04 SE ('medium risk').
39-41
This is of interest in light of suggestions that *04-SE alleles are associated with rapidly progressive periodontal disease. 42 Our finding that HLA-DRB1*0401 is more strongly associated with ACPA-positive RA than HLADRB1*0404 is consistent with most previous reports, 10, [43] [44] [45] although not all. 46 Subtle differences with other reports of a hierarchy of risk (*044*104*01) 47 may be attributed to differences in the genetic or environmental background, and/or to differences in statistical methods. Unlike some other European populations, 47 our data in common with other large cohorts 17 were consistent with a gene-dose effect of SE alleles, perhaps giving clues as to the role of HLA-DRB1 in RA pathogenesis. We did not find an additional risk from HLA-DRB1*0401/*0404 compound heterozygosity in the sense of a greater than log-additive joint effect of the two alleles on risk.
In contrast to some other studies, this was not an inception cohort, which makes it impossible to determine whether some of the 'susceptibility' effect may have been affected by 'severity' effects. 48 Early reports suggested an influence of RF status on radiographic progression independent of HLA-DRB1, 49 but, in combined analyses, the effect of ACPA on progression appears far stronger than that of RF. 50 Until recently most evidence has been against an ACPA-independent role of HLA-DRB1 SE in progression from early arthritis to RA 7, 51 or in development of erosions. 52 However, evidence is beginning to emerge that HLA-DRB1 SE, ACPA and RF may each make independent contributions to risk of radiographic progression. 53 This is biologically plausible, given the potential effect of RF on immune complex-mediated pathology. The relatively high proportion of nodules in our cohort may simply reflect its historical nature, but if there were a bias towards collection of more severe RA cases, 'severity' effects of RF might partly explain the SE-RF association observed here.
Even in such a large study, it was hard to differentiate the overlapping protective models, so we did not feel it was appropriate to propose yet another protective model. The D 70 model, or almost equivalently the model proposed by Roudier, 29 appeared better than DERAA and slightly better than I 67 . HLA-DRB1*07 alleles (which have both D 70 and I
67
) had a marginally significant patients were less likely to be autoantibody positive (P ¼ 0.02). In order to explore a known gene-environment interaction, 12 we stratified by smoking status and demonstrated the protective effect was only observed in those that have never smoked with borderline evidence of interaction between D 70 and smoking. Our use of logistic regression modelling allowed adjustment for the number of HLA-DRB1 SE alleles. This is equivalent to stratifying the sample by the number of HLA-DRB1 SE alleles. The analysis corresponds closely to relative predispositional effect analysis, 54 and similarly assumes that alleles act multiplicatively on risk. However, logistic regression has the advantage that the unit of analysis is the individual rather than the allele, so that ORs have a real interpretation in terms of risk. As for relative predispositional effect analysis, there is no assumption that all HLA-DRB1 SE alleles contribute equally to disease risk.
All genetic association studies are potentially confounded by population stratification; however, we compared HLA-DRB1 allele frequencies within the control cohorts with each other and with data from the Welsh bone marrow registry (1 680 individuals), with no evidence for any heterogeneity (data not shown). The age of subjects does not appear to introduce significant bias in the UK. 55 In an ideal genetic association study, cases and controls should be matched geographically and by age, but principal components analysis using genomewide data is often used instead. The current dataset does not have genome-wide typing data, so this analysis was not possible.
HLA-DRB1*09 and *0403 (RRRAE and QRRAE) both had OR41.0 compared with other non-SE alleles.
HLA-DRB1*09 has previously been described as an RA susceptibility allele using the relative predispositional effect method, 56 and, in Korea, 57 associated both with RF and ACPA positivity, 17 and with ACPA-negative RA.
58
HLA-DRB1*09 is also emerging as a risk allele in large Caucasian meta-analyses. 47 The current data provide independent confirmation of these HLA-DRB1 non-SE risk effects.
HLA-DRB1*03 has been suggested as a risk allele for ACPA-negative RA, 51, 59, 60 with HLA-DRB1*03 also associated with lower titres of ACPAs in HLA-DRB1 SEpositive individuals. 51 After adjusting for HLA-DRB1 SE, we found a borderline risk from HLA-DRB1*03 compared with other non-HLA-DRB1 SE alleles (OR adjusted for HLA-DRB1 SE 1.16 (1.01-1.32, P ¼ 0.03, Table 4 ), but this did not remain significant after excluding the imputed Oxford data (OR 1.08 (0.94-1.24), P ¼ 0.30) or when restricted to ACPA-negative RA (OR 1.15 (0.96-1.38), P ¼ 0.14). We found no evidence to support a proposed interaction of HLA-DRB1*03 with HLA-DRB1*13.
61
HLA-DRB1*13 had a per-allele, HLA-DRB1 SE-adjusted OR of 1.17 (0.98-1.40), P ¼ 0.082. There was a marginal risk effect of HLA-DRB1*13 for ACPA-negative (OR 1.31 (1.04-1.65), P ¼ 0.021), but not for ACPApositive RA (OR 0.91 (0.72-1.15), P ¼ 0.44). We found no evidence in support of previous suggestions that HLA-DRB1*13 accounts for the protective effect of DERAA against ACPA-positive RA. HLA-DRB1*13 is the commonest DERAA allele; perhaps, the removal of the HLA-DRB1*13 cases in the previous study 47 reduced its power to detect a DERAA effect.
The focus of this paper has been the amino-acid sequence from positions 67-74 encoded by HLA-DRB1, but it is likely that other loci within the major histocompatibility complex may also contribute to RA susceptibility, for example, HLA-DPB1 in ACPA-positive RA, 62 VARS2L 60 and a marker upstream of HLA-B. 60 The complex patterns of linkage disequilibrium across the Susceptibility to rheumatoid arthritis within HLA-DRB1 SL Mackie et al major histocompatibility complex could help to explain the spectrum of effects revealed here. Gene-gene and gene-environment interactions could also be responsible for some of the discrepancies between studies. For example, tobacco exposure may be associated with greater elevations in ACPA titres in HLA-DRB1*01-and *10-positive patients compared with *04-positive patients, 39 and we have shown in our case-only analyses that the protective effect of D70 on autoantibody status was confined to nonsmokers.
The simplicity of the SE hypothesis belies the underlying complexity: having two copies of the HLA-DRB1 SE can be associated with anything from a 2.2-to a 16.0-fold risk of RF-positive, ACPA-positive RA (Table 6 ). It would be worth examining whether classifying individuals according to our combined model might more accurately predict the prognosis of either early/undifferentiated arthritis or RA. Given the spectrum of effects seen within HLA-DRB1, simply measuring autoantibody status or categorising all HLA-DRB1 SE alleles together might lose important prognostic information. Future studies will, it is hoped, directly test our classification of HLA-DRB1 genotypes to determine its utility in clinical practice, and in particular whether it provides additional prognostic information compared with existing risk models. 53 
Patients and methods
All subjects were Caucasian of Northern European descent. Adult-onset RA cases satisfied the 1987 American College of Rheumatology criteria, 63 modified for genetic studies. 64 RA cases (n ¼ 3657) and controls (n ¼ 1357) came from the UK Rheumatoid Arthritis Genetics cohort. 36 RA cases came from Manchester, Sheffield, Leeds, Oxford and London, and controls from Manchester and Sheffield. Stratification by recruitment centre previously revealed no heterogeneity of HLA-DRB1 association with RA, or any difference in HLA-DRB1 SE allele frequencies among the control populations (P ¼ 0.63). 12 Informed consent was obtained in compliance with the Declaration of Helsinki. The study was approved by the North West Research Ethics Committee (MREC 99/8/84).
Laboratory assays
At the time of study recruitment, IgM-RF was measured in routine NHS laboratories using standard nephelometric assays, but ACPA was not routinely measured. Stored sera were available from patients from Manchester, Leeds and Sheffield, and were tested for IgG ACPA (DIASTATt anti-CCP ELISA, Axis-Shield Diagnostics Limited, Cambs, UK). 36 Patients who had ever had titres X40 units/ml and X5.5units/ml were classified as positive for RF and ACPA, respectively. HLA-DRB1 genotyping was performed using commercially available semi-automated PCR-SSOP typing. 12 
Analysis
For each group of alleles tested, we chose the group of comparator (reference) alleles as follows. To estimate risk effects, the du Montcel S allele groups were each compared with du Montcel X (non-S) alleles, 18 and HLA-DRB1 SE alleles and their subtypes were compared with HLA-DRB1 non-SE alleles. To estimate protective effects, HLA-DRB1 non-SE alleles were compared with all other non-SE alleles, adjusting for the number of HLA-DRB1 SE alleles using logistic regression; in addition, a subgroup analysis was performed on those individuals with no HLA-DRB1 SE alleles. Because smoking data was available only for cases, case only analyses were performed comparing ACPA-positive patients with ACPA-negative patients and RF-positive patients with RF-negative patients and then stratified to estimate protective effects in smokers/nonsmokers. For most analyses, per-allele OR and 95% CI were estimated by logistic regression assuming a log-additive genetic model. Lastly, the susceptibility and protective models that best fitted this dataset were combined.
HLA-DRB1 SE alleles were grouped according to the amino-acid sequence at positions 70-74. As in previous work, 20 ). Where only low-resolution or ambiguous high-resolution HLA-DRB1 genotyping data were available (269 individuals), the alleles were assigned to the most likely group, if probability 40.70 based on published population frequencies, otherwise set to missing (29 alleles in 24 individuals). In 280 samples from Oxford, a distinction could not be made between HLA-DRB1*03 and *13 alleles. These were randomly assigned based on the relative *03/*13 frequencies in the rest of the dataset. The analysis was also repeated omitting the Oxford data in order to assess whether this imputation introduced any bias.
We compared the 70 DERAA
74
, D 70 and I 67 protective models, selecting alleles for which the model predictions differed.
Data were analysed using STATA SE, version 10 (StataCorp, Texas, USA). Statistical significance was taken as Po0.05.
For the case-only analysis, logistic regression was used with autoantibody status as outcome (positive for ACPA or RF, versus negative for both) and D 70 and smoking (ever versus never) as predictors. Interaction was tested as departure from a multiplicative joint effect using a likelihood ratio test.
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